(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Bonk.fun’s April Fools Joke Targets Israel, Sparks Debate - 2Instructions to Pick the Right Gold Speculation Procedure: Exploring the Market
- 3Merz: 80% of Syrians in Germany expected to return within three years
- 4From White Elephant to Favorite Things parties, here are all the rules you need to know every kind of gift exchange
- 5Car Investigation: A Survey of \Past the Outside\ Car
- The Excursion to Monetary Proficiency: Individual budget Triumphs
- Tuesday, April 7. Russia’s War On Ukraine: News And Information From Ukraine
- 6 U.S. States for Climbing
- The last penny was pressed by the U.S. Mint in Philadelphia today. Could the nickel and dime be next?
- Energy security rifts widen in Europe
- South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
- 6 Arranging Administrations to Change Your Open air Space
- Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- The most effective method to Guarantee Thorough Inclusion in Senior Protection.
